Lipway/Lipway SR Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Fenofibrate

Indications/Uses

Treatment of hyperlipidemias of type IIa, IIb, III, IV & V in patients who have not responded adequately to diet & other appropriate measures.

Click to view Lipway/Lipway SR detailed prescribing information

Dosage/Direction for Use

Lipway tab Management of primary hypercholesterolemia or mixed dyslipidemia Initially 160 mg daily. Management of elevated serum triglyceride conc Initially 54-160 mg daily. Adjust dose at intervals of 4-8 wk. Max: 160 mg daily. Lipway SR cap Adult 1 cap daily.

Click to view Lipway/Lipway SR detailed prescribing information

Overdosage

View Lipway/Lipway SR overdosage for action to be taken in the event of an overdose.

Administration

Should be taken with food.

Contraindications

Severe renal or hepatic impairment, existing gallbladder disease, photosensitivity. Concomitant w/ HMG CoA reductase inhibitors & other fibrates. Pregnancy & lactation. Childn.

Click to view Lipway/Lipway SR detailed prescribing information

Special Precautions

Discontinue treatment if ASAT & ALAT conc increase to over 3 times upper normal limit. Test liver function every 3 mth. Monitor prothrombin time in patients receiving oral anticoagulants. Muscle damage (including rhabdomyolysis) especially in patients w/ hypoalbuminemia. Patients w/ renal impairment (CrCl <50 mL/min). Elderly ≥65 yr.

Click to view Lipway/Lipway SR detailed prescribing information

Use In Pregnancy & Lactation

Click to view Lipway/Lipway SR detailed prescribing information

Adverse Reactions

Muscle damage (diffuse myalgia, painful sensitivity, weakness) & exceptional cases of rhabdomyolysis. Digestive disorders of the dyspeptic type, elevation of transaminases, hepatitis, photosensitivity, Allergic skin reactions including rashes.

Click to view Lipway/Lipway SR detailed prescribing information

Drug Interactions

Risk of additive undesirable muscular effects w/ other fibrates, HMG-CoA reductase inhibitors. Risk of hemorrhage w/ oral anticoagulants.

Click to view Lipway/Lipway SR detailed prescribing information

Storage

View Lipway/Lipway SR storage conditions for details to ensure optimal shelf-life.

Description

View Lipway/Lipway SR description for details of the chemical structure and excipients (inactive components).

Action

View Lipway/Lipway SR mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Dyslipidaemic Agents

ATC Classification

C10AB05 - fenofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.

Regulatory Classification

Presentation/Packing

Form

Lipway SR MR cap 250 mg

Packing/Price

30's (P1,050.5/pack)

Form

Lipway tab 160 mg

Packing/Price

30's (P1,050.5/box)

Lipway/Lipway SR

fenofibrate

Manufacturer:

Cathay Drug

Distributor:

Cathay YSS